| abstract |
This disclosure relates to the treatment of subjects at risk for chronic kidney disease (CKD), having stage one to five CKD, having hyperphosphataemia, susceptible to or suffering from soft tissue calcification associated with CKD, or susceptible to or suffering from hyperparathyroidism, by orally administering a pharmaceutical composition containing a therapeutically effective amount of lanthanum hydroxycarbonate. |